Community-acquired Pneumonia

Overview

Journal BMJ Clin Evid

Specialty General Medicine

Date 2011 Mar 23

PMID 21418681

Citations 4

Authors

Mark Loeb

Affiliations

Soon will be listed here.

Abstract

Introduction: In the northern hemisphere about 12/1000 people a year (on average) contract pneumonia while living in the community, with most cases caused by Streptococcus pneumoniae. Mortality ranges from about 5% to 35% depending on severity of disease, with a worse prognosis in older people, men, and people with chronic diseases.

Methods And Outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent community-acquired pneumonia? What are the effects of treatments for community-acquired pneumonia in outpatient settings, in people admitted to hospital, and in people receiving intensive care? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (oral, intravenous), different combinations, and prompt administration of antibiotics in intensive-care settings, early mobilisation, influenza vaccine, and pneumococcal vaccine.

Citing Articles

Short- and long-term outcomes after incident pneumonia in adults with chronic kidney disease: a time-dependent analysis from the Stockholm CREAtinine Measurement project.

Su G, Trevisan M, Ishigami J, Matsushita K, Stalsby Lundborg C, Carrero J Nephrol Dial Transplant. 2019; 35(11):1894-1900.

PMID: 31219575 PMC: 7643674. DOI: 10.1093/ndt/gfz119.

Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.

Tedijanto C, Olesen S, Grad Y, Lipsitch M Proc Natl Acad Sci U S A. 2018; 115(51):E11988-E11995.

PMID: 30559213 PMC: 6304942. DOI: 10.1073/pnas.1810840115.

Hospital admission with pneumonia and subsequent persistent risk of chronic kidney disease: national cohort study.

Sundin P, Udumyan R, Fall K, Montgomery S Clin Epidemiol. 2018; 10:971-979.

PMID: 30147376 PMC: 6101736. DOI: 10.2147/CLEP.S169039.

The Prevalence of Oropharyngeal Dysphagia in Danish Patients Hospitalised with Community-Acquired Pneumonia.

Melgaard D, Baandrup U, Bogsted M, Dahl Bendtsen M, Hansen T Dysphagia. 2016; 32(3):383-392.

PMID: 28004179 DOI: 10.1007/s00455-016-9765-z.

References

Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R . Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist. 2001; 7(1):85-96. DOI: 10.1089/107662901750152864. View

Bjorkqvist M, Wiberg B, Bodin L, Barany M, Holmberg H . Bottle-blowing in hospital-treated patients with community-acquired pneumonia. Scand J Infect Dis. 1997; 29(1):77-82. DOI: 10.3109/00365549709008669. View

Koivula I, Sten M, Makela P . Risk factors for pneumonia in the elderly. Am J Med. 1994; 96(4):313-20. DOI: 10.1016/0002-9343(94)90060-4. View

Finch R, Schurmann D, Collins O, KUBIN R, McGivern J, Bobbaers H . Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother. 2002; 46(6):1746-54. PMC: 127227. DOI: 10.1128/AAC.46.6.1746-1754.2002. View

Yu K, Wyer P . Evidence-based emergency medicine/critically appraised topic. Evidence behind the 4-hour rule for initiation of antibiotic therapy in community-acquired pneumonia. Ann Emerg Med. 2008; 51(5):651-62, 662.e1-2. DOI: 10.1016/j.annemergmed.2007.10.022. View

El Moussaoui R, de Borgie C, van den Broek P, Hustinx W, Bresser P, van den Berk G . Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006; 332(7554):1355. PMC: 1479094. DOI: 10.1136/bmj.332.7554.1355. View

Marras T, Nopmaneejumruslers C, Chan C . Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. Am J Med. 2004; 116(6):385-93. DOI: 10.1016/j.amjmed.2003.11.013. View

Fine M, Smith M, Carson C, Mutha S, Sankey S, Weissfeld L . Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996; 275(2):134-41. View

Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M . Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev. 2012; (9):CD004418. PMC: 7017099. DOI: 10.1002/14651858.CD004418.pub4. View

10.

Porath A, Schlaeffer F, Lieberman D . The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect. 1997; 34(1):41-8. DOI: 10.1016/s0163-4453(97)80008-4. View

11.

Pertel P, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M . Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis. 2008; 46(8):1142-51. DOI: 10.1086/533441. View

12.

Iezzoni L, Moskowitz M . A clinical assessment of MedisGroups. JAMA. 1988; 260(21):3159-63. DOI: 10.1001/jama.260.21.3159. View

13.

Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M . Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol. 1993; 137(9):977-88. DOI: 10.1093/oxfordjournals.aje.a116770. View

14.

Murphy T, Henderson F, CLYDE Jr W, Collier A, Denny F . Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol. 1981; 113(1):12-21. DOI: 10.1093/oxfordjournals.aje.a113061. View

15.

Houston M, Silverstein M, Suman V . Risk factors for 30-day mortality in elderly patients with lower respiratory tract infection. Community-based study. Arch Intern Med. 1997; 157(19):2190-5. View

16.

Mundy L, Leet T, Darst K, Schnitzler M, Dunagan W . Early mobilization of patients hospitalized with community-acquired pneumonia. Chest. 2003; 124(3):883-9. DOI: 10.1378/chest.124.3.883. View

17.

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

18.

Foy H, COONEY M, Allan I, KENNY G . Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA. 1979; 241(3):253-8. View

19.

Almirall J, Gonzalez C, Balanzo X, Bolibar I . Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest. 1999; 116(2):375-9. DOI: 10.1378/chest.116.2.375. View

20.

Berjohn C, Fishman N, Joffe M, Edelstein P, Metlay J . Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine (Baltimore). 2008; 87(3):160-166. DOI: 10.1097/MD.0b013e318178923a. View